Cancer Patients See High Seroconversion Rates After COVID Vax

June 11, 2021 9:21 am

Dampened responses seen in those with hematological malignancies, however
by Mike Bassett

Patients with cancer who were vaccinated against COVID-19 achieved high seroconversion rates, a single-center study found.

The rate of seroconversion was especially high among patients with solid tumors … Read more

Novel vaccine safe, effective in ovarian cancer subset

June 11, 2021 8:51 am

By Jennifer Southall

A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more

Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer

June 8, 2021 11:28 am

by Victoria Forster, PhD

Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1Read more

Pafolacianine Sodium, NIRF Imaging Adjunct May Yield Benefit in FR+ Ovarian Cancer

June 8, 2021 11:16 am

Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.… Read more

Mirvetuximab Soravtansine Plus Bevacizumab Looks Promising in Platinum-Agnostic Ovarian Cancer

June 7, 2021 11:22 am

The combination of mirvetuximab soravtansine and bevacizumab produces “impressive antitumor activity” in patients with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, according to researchers.… Read more

No Difference in Survival Noted With Longer Duration of Bevacizumab for Ovarian Cancer

June 7, 2021 11:18 am

Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.

For patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, prolonged treatment

Read more

Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers

June 5, 2021 9:00 am

An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 … Read more

SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting

June 4, 2021 11:10 am

PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) — SOTIOa clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a Read more

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

June 4, 2021 10:34 am

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more

HIPEC With Carboplatin for Platinum-Sensitive Recurrent Ovarian Cancer: Safety and Outcomes

June 2, 2021 12:29 pm

In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free … Read more

Cancer Patients Develop ‘Adequate’ Immune Response to COVID Vax

May 28, 2021 11:09 am

In a prospective study in Israel, 90% of cancer patients were seropositive for antibodies

The vast majority of patients undergoing active systemic therapy for cancer exhibited an adequate immune response to the Pfizer/BioNTech COVID-19 vaccine, according to a prospective cohort … Read more

Breakthrough Therapy Designation Granted to VS-6766 Plus Defactinib for Pretreated Low-Grade Serous Ovarian Cancer

May 25, 2021 5:00 pm

A RAF/MEK plus FAK inhibitor combination will be given an expedited review by the FDA as therapy for patients with recurrent low-grade serous ovarian cancer.

By

The combination of the RAF/MEK inhibitor, VS-6766, plus the FAK inhibitor, defactinib, … Read more

Atezolizumab Regimen Fails to Extend PFS in Newly Diagnosed Ovarian Cancer

May 24, 2021 3:00 pm

By Jennifer Southall

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical OncologyRead more

‘Devastated and Sad’ After 36 Years of Research — Early Detection of Ovarian Cancer Doesn’t Save Lives

May 19, 2021 1:00 pm

By Professor Ian Jacobs

I was motivated to improve the outcome for women with ovarian cancer by my experience as a junior doctor in London in 1985. But 36 years on, the results aren’t what we’d hoped.

My colleages’ and

Read more

Disappointment: Screening for Ovarian Cancer Does Not Cut Deaths

May 13, 2021 12:00 pm

By Pam Harrison

Results from a huge British trial that involved more than 200,000 women who were followed for a median of 16 years have turned out negative. Investigators found that annual screening for ovarian cancer with either multimodal screening … Read more

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4, 2021 2:00 pm

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

By … Read more

Smart Cell Therapies for Solid Cancers Ready to Move Toward Clinical Trials

April 28, 2021 7:00 pm

By Lindzi Wessel

Immunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of malignancies, leaving few treatment options for most cancer patients with solid tumors. Now, in two Read more

Carboplatin Alone Not Adequate for Ovarian Cancer in Frail Seniors

April 27, 2021 6:00 pm

Worse survival than with combination carboplatin-paclitaxel regimens for vulnerable older patients with ovarian cancer.

For vulnerable older patients with ovarian cancer, single-agent carboplatin is less active, with worse survival, than combination carboplatin-paclitaxel regimens, according to a study published online April

Read more

Ovarian Cancer and a New Era for Clinical Trials

April 20, 2021 9:00 am

At Clearity we are intent on bringing the future of ovarian cancer treatment to women today. It’s exciting to have the opportunity to work with other organizations who share our vision. Teckro’s goal is to make clinical trials more accessible, Read more

Luci Berardi: Writing a New Chapter on Ovarian Cancer

April 15, 2021 10:30 am

Luci Berardi had known for three months that something was wrong. As a yoga practitioner and instructor, she was very much in tune with her body, and the changes she was noticing were odd and disconcerting.

First there was the … Read more